Literature DB >> 22308098

Factors influencing survival in patients undergoing palliative bypass for pancreatic adenocarcinoma.

Phillip J Gray1, Jingya Wang, Timothy M Pawlik, Barish H Edil, Richard Schulick, Ralph H Hruban, Harry Dao, John Cameron, Christopher Wolfgang, Joseph M Herman.   

Abstract

PURPOSE: The purpose of this study is to identify factors predictive of early mortality following palliative bypass in patients with previously unsuspected advanced pancreatic adenocarcinoma to provide a basis for the selection of appropriate therapies.
METHODS: All patients with pancreatic adenocarcinoma who underwent a bypass procedure at our institution between 9/30/1994 and 1/31/2006 were reviewed. Patients with peri-operative mortality were excluded from the analysis. Univariate analysis was performed on peri-operative data to identify factors associated with early mortality (death within 6 months of surgery). Patients having multiple risk factors were assigned an overall prognostic score based on the sum of these factors.
RESULTS: Of the 397 patients with pancreatic adenocarcinoma analyzed, four factors were found to predict early mortality following palliative bypass: Presence of distant metastatic disease (HR 2.59, P < 0.0001), poor tumor differentiation (HR 1.71, P = 0.009), severe pre-operative nausea and vomiting (HR 1.48, P = 0.013), and lack of previous placement of a biliary stent (HR 1.36, P = 0.048). Patients with a prognostic score of 0 were significantly more likely to survive past 6 months than patients with a prognostic score of 1 (HR 2.71, P < 0.0001), 2 (HR 3.70, P < 0.0001), or ≥3 (HR 5.63, P < 0.0001).
CONCLUSIONS: In a cohort of patients undergoing a palliative bypass procedure, specific peri-operative factors can be used to identify patients who are at risk of early mortality. These factors may be helpful in selecting appropriate interventions for this group of patients.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22308098      PMCID: PMC3578321          DOI: 10.1002/jso.23047

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  20 in total

1.  Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients.

Authors:  K F D Kuhlmann; S M M de Castro; J G Wesseling; F J W ten Kate; G J A Offerhaus; O R C Busch; T M van Gulik; H Obertop; D J Gouma
Journal:  Eur J Cancer       Date:  2004-03       Impact factor: 9.162

2.  Palliative surgery for unresectable pancreatic and periampullary cancer: a reappraisal.

Authors:  Mickael Lesurtel; Nidal Dehni; Emmanuel Tiret; Rolland Parc; François Paye
Journal:  J Gastrointest Surg       Date:  2006-02       Impact factor: 3.452

3.  [Prognostic factors in advanced pancreatic cancer. Multivariate analysis of predictive survival score. University Surgery Association].

Authors:  B Trigui; A Barrier; A Flahault; M Huguier
Journal:  Ann Chir       Date:  2000-09

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

Review 5.  Laparoscopy in the staging of pancreatic cancer.

Authors:  P W Pisters; J E Lee; J N Vauthey; C Charnsangavej; D B Evans
Journal:  Br J Surg       Date:  2001-03       Impact factor: 6.939

6.  Prognostic factors in the palliation of pancreatic cancer.

Authors:  F J F Engelken; V Bettschart; M Q Rahman; R W Parks; O J Garden
Journal:  Eur J Surg Oncol       Date:  2003-05       Impact factor: 4.424

7.  Pooling of prognostic studies in cancer of the pancreatic head and periampullary region: the Triple-P study. Triple-P study group.

Authors:  C B Terwee; E J Nieveen Van Dijkum; D J Gouma; K E Bakkevold; J H Klinkenbijl; T P Wade; B A van Wagensveld; A Wong; J H van der Meulen
Journal:  Eur J Surg       Date:  2000-09

Review 8.  Pancreatic stenting for malignant ductal obstruction.

Authors:  G Costamagna; M Mutignani
Journal:  Dig Liver Dis       Date:  2004-09       Impact factor: 4.088

9.  Predicting resectability of periampullary cancer with three-dimensional computed tomography.

Authors:  Michael G House; Charles J Yeo; John L Cameron; Kurt A Campbell; Richard D Schulick; Steven D Leach; Ralph H Hruban; Karen M Horton; Elliot K Fishman; Keith D Lillemoe
Journal:  J Gastrointest Surg       Date:  2004 Mar-Apr       Impact factor: 3.452

10.  Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy.

Authors:  Sunil Krishnan; Vishal Rana; Nora A Janjan; Gauri R Varadhachary; James L Abbruzzese; Prajnan Das; Marc E Delclos; Morris S Gould; Douglas B Evans; Robert A Wolff; Christopher H Crane
Journal:  Cancer       Date:  2007-07-01       Impact factor: 6.860

View more
  3 in total

1.  Operative procedures for unresectable pancreatic cancer: does operative bypass decrease requirements for postoperative procedures and in-hospital days?

Authors:  John M Lyons; Ami Karkar; Camilo C Correa-Gallego; Michael I D'Angelica; Ronald P DeMatteo; Yuman Fong; T Peter Kingham; William R Jarnagin; Murray F Brennan; Peter J Allen
Journal:  HPB (Oxford)       Date:  2012-05-15       Impact factor: 3.647

Review 2.  Pancreatic cancer-A disease in need: Optimizing and integrating supportive care.

Authors:  Gordon T Moffat; Andrew S Epstein; Eileen M O'Reilly
Journal:  Cancer       Date:  2019-08-05       Impact factor: 6.860

3.  Pancreatic cancer in an Asian population.

Authors:  Pradermchai Kongkam; Pichit Benjasupattananun; Pongpeera Taytawat; Patpong Navicharoen; Viroj Sriuranpong; Laddawan Vajragupta; Naruemon Klaikaew; Wiriyaporn Ridtitid; Sombat Treeprasertsuk; Rungsun Rerknimitr; Pinit Kullavanijaya
Journal:  Endosc Ultrasound       Date:  2015 Jan-Mar       Impact factor: 5.628

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.